Recent developments in the management of cancer pain in Japan: Education, clinical guidelines and basic research

Japanese Journal of Clinical Oncology

Volumn 42, Issue 12, 2012, Pages 1120-1127

  Yamaguchi, Takashi ^a,b   Narita, Minoru ^c   Morita, Tatsuya ^d   Kizawa, Yoshiyuki ^b   Matoba, Motohiro ^e  

^a TEINE KEIJINKAI HOSPITAL   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c HOSHI UNIVERSITY   (Japan)

^d SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER   (Japan)

Author keywords

Basic research; Cancer pain management; Education; Japan; Palliative care

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DOPAMINE RECEPTOR BLOCKING AGENT; FENTANYL; HISTAMINE H2 RECEPTOR ANTAGONIST; KETAMINE; LAXATIVE; MORPHINE; MU OPIATE RECEPTOR AGONIST; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OLANZAPINE; OPIATE; OXYCODONE; PARACETAMOL; PENTAZOCINE; PROSTAGLANDIN E1 DERIVATIVE; PROTON PUMP INHIBITOR; PSYCHOSTIMULANT AGENT; SCOPOLAMINE BUTYL BROMIDE; UNINDEXED DRUG;

ANXIETY; ARTICLE; BONE METASTASIS; BONE PAIN; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CHRONIC PAIN; CONSTIPATION; DELIRIUM; DISEASE SEVERITY; DROWSINESS; DRUG DEPENDENCE; EDUCATION PROGRAM; EPIGASTRIC PAIN; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HUMAN; INTESTINE OBSTRUCTION; JAPAN; KNOWLEDGE; MALIGNANT PSOAS SYNDROME; MEDICAL RESEARCH; MUSCLE DISEASE; NAUSEA; NERVE BLOCK; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATIENT EDUCATION; PERINEAL PAIN; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREVALENCE; SCIENCE; SLEEP DISORDER; THORAX PAIN; VOMITING;

ANALGESICS, OPIOID; EDUCATION, MEDICAL; EVIDENCE-BASED MEDICINE; HUMANS; JAPAN; NEOPLASMS; PAIN; PAIN MANAGEMENT; PALLIATIVE CARE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 84870466021     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys155     Document Type: Article

References (57)

1. Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin 2011;61:157-82.
2. Teunissen SCCM, Wesker W, Kruitwagen C, de Haes HCJM, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007;34:94-104.
3. van den Beuken-van Everdingen M, de Rijke J, Kessels A, Schouten H, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-49.
4. Ger LP, Ho ST, Wang JJ, Cherng CH. The prevalence and severity of cancer pain: a study of newly-diagnosed cancer patients in Taiwan. J Pain Symptom Manage 1998;15:285-93.
5. Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995;13:748-55.
6. Vuorinen E. Pain as an early symptom in cancer. Clin J Pain 1993;9:272-8.
7. Esther Kim J-E, Dodd MJ, Aouizerat BE, Jahan T, Miaskowski C. A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Symptom Manage 2009;37:715-36.
8. Yamagishi A, Morita T, Miyashita M, et al. Pain intensity, quality of life, quality of palliative care, and satisfaction in outpatients with metastatic or recurrent cancer: A japanese, nationwide, region-based, multicenter survey. J Pain Symptom Manage 2012;43:503-14.
9. Morita T, Fujimoto K, Namba M, et al. Palliative care needs of cancer outpatients receiving chemotherapy: an audit of a clinical screening project. Support Care Cancer 2007;16:101-7.
10. Yamagishi A, Morita T, Miyashita M, Kimura F. Symptom prevalence and longitudinal follow-up in cancer outpatients receiving chemotherapy. J Pain Symptom Manage 2009;37:823-30.
11. World Health Organization. Access to controlled medications programme: framework. 2007. http://www.who.int/medicines/areas/ quality_safety/Framework_ACMP_withcover.pdf (30 April 2012, date last accessed).
12. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-6.
13. Okuyama T, Akechi T, Yamashita H, et al. Oncologists' recognition of supportive care needs and symptoms of their patients in a breast cancer outpatient consultation. Jpn J Clin Oncol 2011;41:1251-8.
14. Japan Medical Association. Gan-iryo ni okeru kanwakea ni kansuru ishi no ishikityousa [Japanese]. 2008. http://dl.med.or.jp/dl-med/teireikaiken/ 20080903_3.pdf.
15. Schuit KW, Bender W, Meijler WJ, Otter R, Meyboom-Dejong B, Sleijfer DT. Learning effects of a workshop in palliative cancer care for general practitioners. J Cancer Educ 1999;14:18-22.
16. Yamamoto R. PEACE kensyukai jyukouniyori ishi no kanwakeanitaisuruchishiki ha koujyousuruka? In: Poster Session Presented at the 17th Congress of the Japanese Society for Palliative Medicine, 22-23 June 2012. Kobe, Japan (in Japanese).
17. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54.
18. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587- 93.
19. Jost L. Management of cancer pain: ESMO clinical recommendations. Ann Oncol 2007;18 (Suppl. 2):ii92-4.
20. Kvale PS, Selecky PA, Prakash UB. Palliative care in lung cancer: ACCP Evidence-Based Clinical Practice Guidelines. 2nd edn. Chest 2007;132:368S-403S.
21. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain. Cancer 2002;94:832-9.
22. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Adult cancer pain. http://www.nccn.org/ professionals/physician_gls/PDF/pain.pdf.
23. Leser J, editor. Bonica's Management of Pain. 3rd edn. Lippincott Williams and Wilkins 2001.
24. Berger AS, Shuster JL, Von Roenn JH, editors. Principles and Practice of Palliative Care and Supportive Oncology. 3rd edn. Lippincott Williams & Wilkins, a Wolters Kluwer Business 2007.
25. Doyle D, Hanks GWC, Cherny NI, Calman K, editors. Oxford Textbook of Palliative Medicine. 3rd edn. Oxford University Press 2005.
26. McMahon SB, Koltzenburg M, editors. Wall and Melzack's Textbook of Pain. 5th edn. Elsevier Churchill Livingstone 2006.
27. Walsh D, ed. Palliative Medicine. Saunders Elsevier 2009.
28. Bruera E, Higginson IJ, Ripamonti C, von Gunten C, editors. Textbook of Palliative Medicine. Hodder Arnold 2006.
29. Niikura K, Narita M, Butelman ER, et al. Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission. Trends Pharmacol Sci 2010;31:299-305.
30. Ozaki S, Narita M, Narita M, et al. Suppression of the morphine-induced rewarding effect in the rat with neuropathic pain: implication of the reduction in mu-opioid receptor functions in the ventral tegmental area. J Neurochem 2002;82:1192-8.
31. Ozaki S, Narita M, Narita M, et al. Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2. Neuroscience 2003;116:89-97.
32. Ozaki S, Narita M, Narita M, et al. Role of extracellular signal-regulated kinase in the ventral tegmental area in the suppression of the morphine-induced rewarding effect in mice with sciatic nerve ligation. J Neurochem 2004;88:1389-97.
33. Narita M, Suzuki M, Imai S, et al. Molecular mechanism of changes in the morphine-induced pharmacological actions under chronic pain-like state: suppression of dopaminergic transmission in the brain. Life Sci 2004;74:2655-73.
34. Narita M, Oe K, Kato H, et al. Implication of spinal protein kinase C in the suppression of morphine-induced rewarding effect under a neuropathic pain-like state in mice. Neuroscience 2004;125:545-51.
35. Oe K, Narita M, Imai S, et al. Inhibition of the morphine-induced rewarding effect by direct activation of spinal protein kinase C in mice. Psychopharmacology (Berl) 2004;177:55-60.
36. Narita M, Imai S, Oe K, et al. Induction of c-fos expression in the mouse brain associated with hyperalgesia induced by intrathecal injection of protein kinase C activator. Brain Res 2004;1015:189-93.
37. Narita M, Kishimoto Y, Ise Y, et al. Direct evidence for the involvement of the mesolimbic kappa-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. Neuropsychopharmacology 2005;30:111-8.
38. Wise RA, Bozarth MA. Action of drugs of abuse on brain reward systems: an update with specific attention to opiates. Pharmacol Biochem Behav 1982;17:239-43.
39. Kling MA, Carson RE, Borg L, et al. Opioid receptor imaging with positron emission tomography and [(18)F] cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 2000;295:1070-76.
40. Narita M, Funada M, Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol Ther 2001;89:1-15.
41. Olmstead MC, Franklin KB. The development of a conditioned place preference to morphine: effects of microinjections into various CNS sites. Behav Neurosci 1997;111:1324-34.
42. Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 1988;244:1067-80.
43. Wang XM, Zhou Y, Spangler R, et al. Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. Brain Res Mol Brain Res 1999;66:184-7.
44. Niikura K, Narita M, Narita M, et al. Direct evidence for the involvement of endogenous beta-endorphin in the suppression of the morphine induced rewarding effect under a neuropathic pain-like state. Neurosci Lett 2008;435:257-62.
45. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001;111:106S-12S.
46. Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med 2009;10:654-62.
47. Herndon CM, Jackson KC, II, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 2002;22:240-50.
48. Iasnetsov VV, Drozd IuV, Shashkov VS. Emetic and antiemetic properties of regulatory peptides. Biull Eksp Biol Med 1987;103:586-8.
49. Rousseau P. Nonpain symptom management in terminal care. Clin Geriatr Med 1996;12:313-27.
50. Torigoe K, Nakahara K, Rahmadi M, et al. Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain. Anesthesiology 2012;116:159-69.
51. O'Brien EM, Waxenberg LB, Atchison JW, et al. Negative mood mediates the effect of poor sleep on pain among chronic pain patients. Clin J Pain 2010;26:310-9.
52. Zgierska A, Brown RT, Zuelsdorff M, et al. Sleep and daytime sleepiness problems among patients with chronic noncancerous pain receiving longterm opioid therapy: a cross-sectional study J Opioid Manag 2007;3:317-27.
53. Narita M, Niikura K, Nanjo-Niikura K, et al. Sleep disturbances in a neuropathic pain-like condition in the mouse are associated with altered GABAergic transmission in the cingulate cortex. Pain 2011;152:1358-72.
54. Bateson AN. The benzodiazepine site of the GABAA receptor: an old target with new potential? Sleep Med 2004;5:S9-S15.
55. Gottesmann C. GABA mechanisms and sleep. Neuroscience 2002;111:231-9.
56. Bormann J. Electrophysiology of GABAA and GABAB receptor subtypes. Trends Neurosci 1988;11:112-6.
57. Inomata N, Tokutomi N, Oyama Y, Akaike N. Intracellular picrotoxin blocks pentobarbital-gated Cl2 conductance. Neurosci Res 1988;6:72-5.